Sanofi has terrific first quarter, but next 3 will be tough

Sanofi ($SNY) had a good first quarter with higher revenues and profits, but executives acknowledge that with Plavix weeks away from coming off patent, the next 12 months will be tough. The French com…
Read the full story: News